New inhaled drug tested in healthy volunteers for lung scarring disease
NCT ID NCT06746064
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested the safety and how the body handles an inhaled drug called CHF10073 in 155 healthy volunteers. The drug is being developed for pulmonary fibrosis, a serious lung-scarring condition. The trial looked at different single and multiple doses, and also checked how another drug (itraconazole) affects CHF10073 levels. Since this is a Phase 1 study in healthy people, it does not test if the drug actually treats the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CHF10073 (inhaled drug)
What this could lead to
If successful, this could support further testing of CHF10073 as a potential treatment for pulmonary fibrosis.
What could go wrong
This is a very early Phase 1 study in healthy people, not patients. It only checks safety and drug levels, not whether the drug works for the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
SGS Belgium NV Clinical Pharmacology Unit
Edegem, 2650, Belgium